<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD, FEBO:</roleName><forename type="first">Christoph</forename><surname>Tappeiner</surname></persName>
							<email>christoph.tappeiner@uveitis-zentrum.de.</email>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Schenck</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Sandra Schenck</orgName>
								<orgName type="institution">MPH: German Rheumatism Research Centre Berlin</orgName>
								<address>
									<settlement>MSc</settlement>
									<region>Martina Niewerth</region>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Leibniz Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martina</forename><surname>Niewerth</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Sandra Schenck</orgName>
								<orgName type="institution">MPH: German Rheumatism Research Centre Berlin</orgName>
								<address>
									<settlement>MSc</settlement>
									<region>Martina Niewerth</region>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Leibniz Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arnd</forename><surname>Heiligenhaus</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Arnd Heiligenhaus</orgName>
								<orgName type="institution" key="instit2">FEBO: St. Franziskus Hospital</orgName>
								<address>
									<settlement>Muenster</settlement>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">and University Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kirsten</forename><surname>Minden</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD:</roleName><forename type="first">Jens</forename><surname>Klotsche</surname></persName>
						</author>
						<author>
							<persName><forename type="first">German</forename><surname>Rheumatism</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Research Centre Berlin</orgName>
								<orgName type="institution" key="instit2">Leibniz Institute</orgName>
								<address>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">and Inselspital</orgName>
								<orgName type="institution">St. Franzis-kus Hospital</orgName>
								<address>
									<settlement>Muenster</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">University of Bern</orgName>
								<address>
									<settlement>Bern</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">Research Centre Berlin</orgName>
								<orgName type="institution" key="instit2">Leibniz Institute, and Charit e Univer-sity Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="institution">Alimera Sciences</orgName>
								<address>
									<settlement>Allergan</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution">MSD Sharp and Dohme</orgName>
								<address>
									<settlement>Pfizer, Santen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">FEBO</orgName>
								<orgName type="department" key="dep2">Department of Ophthalmology at St</orgName>
								<orgName type="institution">Franziskus Hos-pital</orgName>
								<address>
									<addrLine>Hohenzollernring 74</addrLine>
									<postCode>48145</postCode>
									<settlement>Muenster</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">F59EE490926E0060597A4C9E8FFFD47F</idno>
					<idno type="DOI">10.1002/acr.22649</idno>
					<note type="submission">Submitted for publication April 13, 2015; accepted in revised form June 30, 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:43+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objective.</s><s>Based on a nationwide database, this study analyzed the influence of methotrexate (MTX), tumor necrosis factor (TNF) inhibitors, and a combination of the 2 medications on uveitis occurrence in juvenile idiopathic arthritis (JIA) patients.</s><s>Methods.</s><s>Data from the National Paediatric Rheumatological Database in Germany were used in this study.</s><s>Between 2002  and 2013, data from JIA patients were annually documented at the participating pediatric rheumatologic sites.</s><s>Patients with a JIA disease duration of &lt;12 months at initial documentation and ‡2 years of followup were included in this study.</s><s>The impact of antiinflammatory treatment on the occurrence of uveitis was evaluated by discrete-time survival analysis.</s><s>Results.</s><s>A total of 3,512 JIA patients (mean 6 SD age 8.3 6 4.8 years, 65.7% female, 53.2% antinuclear antibody positive, and mean 6 SD age at arthritis onset 7.8 6 4.8 years) fulfilled the inclusion criteria.</s><s>Mean 6 SD total followup time was 3.6 6 2.4 years.</s><s>Uveitis developed in a total of 180 patients (5.1%) within 1 year after arthritis onset.</s><s>Uveitis onset after the first year was observed in another 251 patients (7.1%).</s><s>Disease-modifying antirheumatic drug (DMARD) treatment in the year before uveitis onset significantly reduced the risk for uveitis as follows: MTX: hazard ratio (HR) 0.63, P 5 0.022; TNF inhibitors: HR 0.56, P &lt; 0.001; and a combination of the 2 medications: HR 0.10, P &lt; 0.001.</s><s>Patients treated with MTX within the first year of JIA had an even a lower uveitis risk (HR 0.29, P &lt; 0.001).</s><s>Conclusion.</s><s>The use of DMARDs in JIA patients significantly reduced the risk for uveitis onset.</s><s>Early MTX use within the first year of disease and the combination of MTX with a TNF inhibitor had the highest protective effect.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic arthritides with onset before age 16 years <ref type="bibr" target="#b0">(1)</ref><ref type="bibr" target="#b1">(2)</ref><ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref>.</s><s>Uveitis occurs at a rate of approximately 9-13% in these patients <ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b5">(6)</ref><ref type="bibr" target="#b6">(7)</ref> and may cause vision-threatening complica-tions <ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref>.</s><s>The major known risk factors for the development of uveitis are JIA oligoarthritis, young age at arthritis onset, short duration of disease, and antinuclear antibody (ANA) positivity <ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref>.</s><s>Previous epidemiologic data suggest that the prevalence of uveitis in JIA varies among different geographic regions, with a higher rate in north-Supported by Pfizer Pharma, Germany (Forschungsf€ orderung Rheumatologie).</s><s>The National Paediatric Rheumatological Database is financially supported by the German Children's Arthritis Foundation (Deutsche Kinderrheuma-Stiftung).</s></p><p><s>ern countries, such as the Scandinavian countries and Germany, and a lower frequency in eastern and southern Asia <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b14">15)</ref>.</s><s>Systemic antiinflammatory treatment with synthetic and/or biologic disease-modifying antirheumatic drugs (DMARDs) is often required to achieve inactivity of arthritis <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b17">(17)</ref><ref type="bibr" target="#b18">(18)</ref><ref type="bibr" target="#b19">(19)</ref><ref type="bibr" target="#b20">(20)</ref><ref type="bibr" target="#b21">(21)</ref><ref type="bibr" target="#b22">(22)</ref>.</s><s>Based on data from 2 randomized controlled trials <ref type="bibr" target="#b20">(20,</ref><ref type="bibr" target="#b23">23)</ref>, methotrexate (MTX) is the first-choice treatment for active arthritis in JIA.</s><s>On the other hand, biologic DMARDs, mainly tumor necrosis factor (TNF) inhibitors, offer a further option for treatment-refractory disease <ref type="bibr" target="#b18">(18,</ref><ref type="bibr" target="#b22">22,</ref><ref type="bibr" target="#b24">(24)</ref><ref type="bibr" target="#b25">(25)</ref><ref type="bibr" target="#b26">(26)</ref><ref type="bibr" target="#b27">(27)</ref><ref type="bibr" target="#b28">(28)</ref>.</s><s>Previous reports suggest that systemic antiinflammatory treatment in JIA may influence whether uveitis develops in patients with JIA <ref type="bibr" target="#b29">(29,</ref><ref type="bibr" target="#b30">30)</ref>.</s></p><p><s>Using a prospective nationwide pediatric rheumatologic database (NPRD), we performed a longitudinal analysis in a large cohort of JIA patients to evaluate the impact of DMARDs on the occurrence of uveitis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PATIENTS AND METHODS</head><p><s>Data acquisition: rheumatologic and ophthalmologic documentation.</s><s>The study was based on JIA patients who fulfilled the International League of Associations for Rheumatology (ILAR) criteria <ref type="bibr" target="#b31">(31)</ref> and who were included in the NPRD between January 2002 and December 2013.</s><s>The database design has been described in detail previously by our group <ref type="bibr" target="#b6">(7,</ref><ref type="bibr" target="#b32">32)</ref>.</s><s>The following clinical parameters were reported at yearly intervals by the pediatric rheumatologists: the patient's age, sex, diagnosis (JIA category), age at onset of arthritis, systemic treatment, physicians' global assessment of disease activity, number of swollen or tender joints, number of joints with limited range of motion, and extraarticular manifestations, such as the presence of uveitis.</s><s>Additionally, laboratory results such as the presence of ANA and rheumatoid factor (RF) were also reported.</s><s>Patients (or their parents) judged their overall well-being on a numeric rating scale (range 0-10).</s></p><p><s>In addition, they assessed their functional status by applying the Childhood Health Assessment Questionnaire (C-HAQ).</s><s>The C-HAQ disability index may range from 0 to 3. A value of zero indicates no functional disability, and values between 0 and 1.0 represent mild to moderate disability <ref type="bibr" target="#b33">(33)</ref>.</s><s>The Juvenile Arthritis Disease Activity Score (JADAS-10) and the clinical JADAS (cJADAS-10) were developed as composite tools for scoring disease activity in JIA.</s><s>The JADAS-10 is calculated as the arithmetic sum of the scores of the following variables: physician global rating of disease activity; parent/child rating of well-being; active joint count, assessed in 10 joints; and erythrocyte sedimentation rate, normalized to a 0-10 scale.</s><s>The cJADAS-10 is calculated as the sum of the first 3 variables.</s><s>JADAS-10 and cJADAS-10 values .10</s><s>classify patients as being in a high active disease state, according to Consolaro et al <ref type="bibr" target="#b34">(34,</ref><ref type="bibr" target="#b35">35)</ref>.</s></p><p><s>Inclusion criteria and data analysis.</s><s>To assess the impact of different treatments on the occurrence of uveitis, JIA patients with a JIA disease duration of ,12 months at first documentation and $2 years of followup were included in this analysis.</s></p><p><s>Clinical and demographic characteristics, systemic antiinflammatory treatment, and onset of uveitis are reported by using standard descriptive statistics.</s><s>Baseline sociodemographic and clinical characteristics of patients without uveitis, those who develop uveitis within the first year, and those with uveitis onset during followup years were compared by using multinomial logistic regression models.</s><s>Multivariable logistic regression analysis was conducted to test the baseline risk factors of sex, age at JIA onset, disease duration, ILAR category, ANA positivity, and disease activity on the risk of uveitis in the total sample.</s><s>The followup assessments were conducted annually.</s><s>To examine the impact of disease activity, MTX, and TNF inhibitor therapy on uveitis onset, we used discrete-time survival analysis <ref type="bibr" target="#b36">(36)</ref> adjusted for ANA positivity, ILAR category, age at JIA onset, disease duration, and systemic therapy with glucocorticoids.</s><s>Using this method, the hazard of uveitis onset was estimated for each year during the followup period.</s><s>Discrete-time survival analysis started with patients who had no history of uveitis at the first documentation; the 180 patients in whom uveitis developed in the first year were dropped for this analysis.</s><s>Once uveitis occurred, the subsequent followup years were dropped for these patients.</s><s>To test the hypotheses, treatment in the year before uveitis onset or in the year before the last documentation was used to assess whether uveitis developed after treatment with MTX and/or TNF inhibitors or disease activity was higher, respectively.</s><s>The interaction terms of MTX 3 cJADAS-10 and TNF inhibitors 3 cJADAS-10 were entered into the regression analyses for modeling the higher disease activity of patients treated with DMARDs compared to those who were not.</s><s>Other variables were entered as time-invariant and time-dependent predictors into the model.</s><s>The discrete-time survival model was estimated by the complementary log-log function, as it provides consistent estimates of proportional hazards parameters, regardless of the interval length or the size of the failure rate <ref type="bibr" target="#b36">(36,</ref><ref type="bibr" target="#b37">37)</ref>.</s><s>Meaningful thresholds for age at arthritis onset and cJADAS-10</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Significance &amp; Innovations</head><p><s>Based on a nationwide database in Germany, we analyzed the influence of methotrexate (MTX), tumor necrosis factor (TNF) inhibitors, and a combination of the two on uveitis occurrence in a total of 3,512 juvenile idiopathic arthritis (JIA) patients.</s></p><p><s>Oligoarthritis patients age ,3 years and with a high disease activity at baseline (clinical Juvenile Arthritis Disease Activity Score .10)</s><s>had a very high risk for subsequent uveitis (33.9%).</s></p><p><s>The use of disease-modifying antirheumatic drugs in JIA patients significantly reduced the risk of uveitis onset.</s></p><p><s>Early MTX use within the first year of disease and the combination of MTX with a TNF inhibitor had the highest protective effect.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>48</head><p><s>Tappeiner et al for its use in the prediction models were calculated by considering the threshold associated with the maximum sum of sensitivity and specificity <ref type="bibr" target="#b38">(38)</ref>.</s><s>A P value of less than 0.05 was considered significant.</s><s>All statistical analyses were conducted using SAS software (version 9.3).</s><s>Regarding ethics approval, the NPRD was approved by the Ethics Committee of Charit e in Berlin and, as appropriate, also by the local ethics committee.</s><s>The study was performed according to the Declaration of Helsinki and conforms to the standards applied in Germany.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Onset of uveitis.</head><p><s>A history of uveitis was recorded in a total of 431 patients: 180 patients (41.8%) developed uveitis already in the first year of documentation.</s><s>Uveitis occurred in the second year in another 60 patients (13.9%), in the third year in 66 additional patients (15.3%), in the fourth year in another 53 patients (12.3%), and in an additional 72 patients (16.7%) later on.</s></p><p><s>Uveitis onset within 1 year after arthritis onset.</s><s>In a multivariable logistic regression analysis, ANA positivity (86.6%; odds ratio [OR] 6.55, 95% confidence interval [95% CI] 4.06-10.56,</s><s>P , 0.001) and a younger age at JIA onset (5.7 years; OR 1.12, 95% CI 1.09-1.16,</s><s>P , 0.001), in addition to JIA category, were highly associated with the early onset of uveitis (n 5 180 patients with uveitis in the first year of disease).</s><s>Patients with uveitis were treated more often with synthetic DMARDs, in particular MTX (41.1% versus 28.9%), and biologic DMARDs, mainly adalimumab (3.0% versus 0.2%), in the first year of JIA.</s><s>Due to the study design, it is not possible to show the temporal relationship of uveitis onset and treatment start, i.e., whether treatment was started as a consequence of uveitis onset or whether uveitis occurred after treatment was initiated.</s><s>Most cases of early uveitis were recorded for the JIA category of oligoarthritis (n 5 136, 75.6% of 180; OR 3.55, 95% CI 2.14-5.35,</s><s>P , 0.001).</s><s>Among them, almost all patients were ANA positive (92.4%;</s><s>OR 7.1, 95% CI 3.54-14.04,</s><s>P , 0.001), and an increased risk for early uveitis was found in oligoarthritis patients with a cJADAS-10 score .10</s><s>(11.9% versus 6.7%; OR 1.88, 95% CI 1.19-2.97,</s><s>P 5 0.007).</s></p><p><s>Uveitis manifestation after the first year of disease.</s><s>Uveitis developed in another 251 patients 2 years (median; interquartile range: 1-3 years) after JIA onset.</s><s>Results of the univariate regression analysis for potential uveitis risk factors are shown in   <ref type="table" target="#tab_0">1</ref>), these parameters were not revealed to be independent risk factors in the multivariate logistic regression model (P .</s><s>0.05 for both).</s></p><p><s>In the subsample of patients with oligoarthritis, patients with age ,3 years at arthritis onset (17.9% versus 6.1%; OR 3.63, 95% CI 2.12-6.23,</s><s>P , 0.001) and with a high active disease at baseline (cJADAS-10 .10,</s><s>16.5% versus 7.6%; OR 2.24, 95% CI 1.32-3.78,</s><s>P 5 0.003) had a higher risk for developing uveitis after the first year of JIA dis-ease.</s><s>Patients age ,3 years and with a high disease activity had a very high risk for subsequent uveitis (33.9%;</s><s>OR 9.29, 95% CI 5.13-16.81,</s><s>P , 0.001) compared to patients who did not meet both conditions (5.2%) at baseline, whereas the risk for uveitis was doubled (11.3%;</s><s>OR 2.31, 95% CI 1.60-3.35,</s><s>P , 0.001) for patients who fulfilled only 1 of the 2 conditions.</s></p><p><s>Impact of systemic antiinflammatory treatment in JIA on uveitis onset.</s><s>Systemic antiinflammatory treatment for all patients without uveitis onset within the first 12 months of JIA (n 5 3,332) is shown in Table <ref type="table" target="#tab_3">2</ref>.</s><s>In the particular year before uveitis onset, a total of 779 JIA patients did not receive DMARD treatment, while 1,801 patients were treated with MTX, 48 patients with TNF inhibitor monotherapy (n 5 38 for etanercept, n 5 5 for adalimumab, and n 5 5 for other), and another 436 patients were treated with a combination of MTX and a TNF inhibitor (n 5 65 for adalimumab, n 5 9 for infliximab, and n 5 362 for etanercept).</s><s>The mean 6 SD cJADAS-10 score in the year before uveitis onset was 3.4 6 4.6 for patients who were treated with a DMARD compared to those who were not (mean 6 SD 2.8 6 3.7).</s><s>Cumulative uveitis incidence for patients without systemic treatment and different immunosuppressive treatment groups is shown in Figure <ref type="figure" target="#fig_0">1</ref>.</s><s>The risk for uveitis was significantly decreased by MTX therapy (hazard ratio (HR) 0.63, 95% CI 0.42-0.94,</s><s>P 5 0.022), TNF inhibitors (HR 0.56, 95% CI 0.38-0.81,</s><s>P 5 0.001), and the combination of MTX and a TNF inhibitor (HR 0.10, 95% CI 0.05-0.23,</s><s>P 5 0.001) compared to no DMARD treatment in the year before uveitis onset after adjusting for ANA status, ILAR category, age at JIA onset, disease duration and cJADAS-10 (Table <ref type="table" target="#tab_4">3</ref>).</s><s>The uveitis incidence was 5.9% (22 of 364 patients with uveitis onset) in JIA patients treated with a combination of MTX and etanercept, whereas it was 1.4% for children taking a combination of MTX and adalimumab (1 patient with uveitis onset of 64 patients).</s><s>Patients with early MTX treatment tended to have a higher disease activity (mean 6 SD cJADAS-10 10.8 6 6.4 versus 6.6 6 5.1 without early MTX).</s><s>The risk for developing uveitis during the subsequent followup was significantly lower for patients who were treated early with MTX, i.e., within the first year of JIA (early MTX: n 5 41 [4.8%] versus no early MTX: n 5 184 [8.5%]; HR 0.29, 95% CI 0.19-0.45,</s><s>P , 0.001) (Figure <ref type="figure" target="#fig_1">2</ref>), whereas uveitis occurred insignificantly less frequently in patients treated with TNF inhibitors during the first year (early use of biologic DMARD: n 5 5 [3.6%] versus no early biologic DMARD: n 5 225 [7.6%]; HR 0.51, 95% CI 0.18-1.47,</s><s>P 5 0.51) (Table <ref type="table" target="#tab_4">3</ref>).</s></p><p><s>The protective effect of DMARDs was slightly more pronounced in the category of patients at high risk for uveitis, namely oligoarthritis and RF-negative polyarthritis (use of MTX: HR 0.59, 95% CI 0.38-0.92,</s><s>P 5 0.020; early use of MTX during the first year after arthritis onset: HR 0.29, 95% CI 0.18-0.48,</s><s>P , 0.001; use of biologic DMARD: HR 0.52, 95% CI 0.29-0.75,</s><s>P , 0.001; early use of biologic DMARDs during the first year after arthritis onset: HR 0.69, 95% CI 0.16-3.07,</s><s>P 5 0.628; and MTX plus TNF inhibitor: HR 0.09, 95% CI 0.05-0.31,</s><s>P , 0.001).</s></p><p><s>Disease activity, measured by using the cJADAS-10, significantly decreased during the followup period (mean 6 SD 7.1 6 5.8 for baseline and 3.6 6 4.0 for last followup); however, an increased cJADAS-10 before uveitis onset was significantly associated with a higher risk for uveitis (mean 6 SD 3.5 6 4.0 for patients without uveitis, 4.6 6 4.2 for patients with uveitis; HR 1.06, 95% CI 1.01-1.12,</s><s>P 5 0.044).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>The introduction of MTX and, later on, TNF inhibitors constitute milestones in the treatment of JIA <ref type="bibr" target="#b39">(39)</ref><ref type="bibr" target="#b40">(40)</ref><ref type="bibr" target="#b41">(41)</ref>.</s><s>Although we know from animal models using guinea pigs that MTX is able to prevent experimental uveitis <ref type="bibr" target="#b42">(42)</ref>, sufficient evidence about a similarly protective effect of DMARDs in humans is still lacking.</s><s>Both MTX and TNF inhibitors have been reported to be efficacious in treating JIA and associated uveitis <ref type="bibr" target="#b21">(21,</ref><ref type="bibr" target="#b22">22,</ref><ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b43">(43)</ref><ref type="bibr" target="#b44">(44)</ref><ref type="bibr" target="#b45">(45)</ref>.</s><s>However, only limited data are available for DMARDs regarding their potential impact on reducing the risk for uveitis onset in JIA.</s><s>A previous retrospective study gave preliminary evidence for such an effect using MTX <ref type="bibr" target="#b29">(29)</ref>, with uveitis developing in 10.5% of 86 JIA patients with MTX monotherapy, compared to 20.2% of 168 patients without MTX (OR 0.46, P 5 0.049; n 5 254).</s><s>In our prospective study of a large cohort of JIA patients, we analyzed the influence of synthetic DMARD and/or biologic DMARD treatment on the risk of uveitis onset in JIA.</s></p><p><s>Overall, uveitis was observed in 12.3% of 3,512 children diagnosed with JIA in our study.</s><s>Apart from geographic variations, this uveitis prevalence is similar to data from other population-based studies <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b46">(46)</ref><ref type="bibr" target="#b47">(47)</ref><ref type="bibr" target="#b48">(48)</ref><ref type="bibr" target="#b49">(49)</ref><ref type="bibr" target="#b50">(50)</ref><ref type="bibr" target="#b51">(51)</ref><ref type="bibr" target="#b52">(52)</ref>.</s><s>In Finland, Kotaniemi et al reported a median onset of uveitis 4 to 5 months after arthritis onset, with uveitis occurring in 49% of patients within the first 3 months after JIA onset and in 90% within the first 4 years (5).</s><s>Grassi et al reported similar data <ref type="bibr" target="#b53">(53)</ref>.</s><s>A few patients might develop uveitis even years after JIA onset <ref type="bibr" target="#b54">(54)</ref>.</s><s>The findings in our study are comparable.</s></p><p><s>There are several known risk factors for uveitis in JIA, e.g., young age at arthritis onset, disease duration, ANA positivity, and JIA category <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b15">16)</ref>.</s><s>Extended oligoarthritis, followed by persistent oligoarthritis, RF-negative polyarthritis, and psoriatic arthritis were found to be the JIA categories at highest risk for uveitis <ref type="bibr" target="#b6">(7,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b55">55)</ref>.</s><s>Interestingly, in Scandinavia the highest risk for uveitis was found in the polyarticular group <ref type="bibr" target="#b56">(56,</ref><ref type="bibr" target="#b57">57)</ref>.</s><s>Although girls are at higher risk for JIA itself, sex has not been found to be an independent risk factor for uveitis <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b55">55)</ref>.</s><s>However, young girls with early onset of arthritis seem to be at higher risk than boys <ref type="bibr" target="#b15">(16)</ref>.</s><s>In our study, we were able to confirm these risk factors, namely JIA category (oligoarthritis, persistent and extended, followed by RF-negative polyarthritis), age at disease onset, and ANA positivity.</s><s>The risk for uveitis was slightly higher in the extended oligoarthritis group than in the persistent one.</s><s>These data compare well with previous studies <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b58">(58)</ref><ref type="bibr" target="#b59">(59)</ref><ref type="bibr" target="#b60">(60)</ref><ref type="bibr" target="#b61">(61)</ref><ref type="bibr" target="#b62">(62)</ref>.</s></p><p><s>High disease activity has been reported to be associated with a higher risk of uveitis occurrence in JIA <ref type="bibr" target="#b53">(53,</ref><ref type="bibr" target="#b63">63)</ref>, but the subsequent clinical course of uveitis appears to be quite independent of arthritis activity <ref type="bibr" target="#b64">(64)</ref>.</s><s>The C-HAQ score is a sensitive tool for evaluating functional outcomes in children with chronic arthritis <ref type="bibr" target="#b65">(65)</ref>.</s><s>In our study, patients with a high C-HAQ score at initial documentation revealed a significantly higher risk for uveitis onset during further followup.</s><s>Such a correlation was also found for the JADAS (also including the ESR as a parameter) and the cJADAS in our study.</s><s>Indeed, the risk for uveitis occurrence during followup was nearly twice as high for patients with a cJADAS .10 at first documentation than for those with a lower JADAS (HR 1.64, P 5 0.047).</s></p><p><s>Apart from demographic and clinical data, further biomarkers to predict uveitis risk for an individual patient are highly desirable.</s><s>Interestingly, ESR has been shown to correlate well with the risk for uveitis <ref type="bibr" target="#b66">(66)</ref><ref type="bibr" target="#b67">(67)</ref><ref type="bibr" target="#b68">(68)</ref><ref type="bibr" target="#b69">(69)</ref>.</s><s>In our study, an ESR .35</s><s>mm/hour at first documentation was associated with a significantly higher risk for uveitis onset during followup (OR 2.0, P , 0.001; univariate analysis) (Table <ref type="table" target="#tab_0">1</ref>).</s><s>This is even more interesting considering that these children were treated more frequently with DMARDs (data not shown).</s></p><p><s>Although there are indications that DMARDs may reduce the risk for uveitis in JIA <ref type="bibr" target="#b29">(29,</ref><ref type="bibr" target="#b49">49)</ref>, such an effect was not clearly confirmed in other studies <ref type="bibr" target="#b70">(70)</ref>, which showed a nearly stable uveitis prevalence despite more frequent use of DMARDs.</s><s>In our large cohort, we found a significantly lower risk for uveitis onset in patients with MTX as a monotherapy than in patients not taking any DMARDs.</s><s>This effect was even stronger if MTX was initiated at an early stage of disease (Figure <ref type="figure" target="#fig_1">2</ref>) or when combined with a TNF inhibitor (Figures <ref type="figure" target="#fig_1">1 and 2</ref>), and even more pronounced in the subgroup analysis for patients at high risk for uveitis, namely RF-negative polyarthritis and oligoarthritis, persistent or extended.</s></p><p><s>Current JIA treatment guidelines of the American College of Rheumatology (ACR) recommendations (1) and the German Society for Paediatric Rheumatology (2) recommend starting MTX when nonsteroidal antiinflammatory drugs (NSAIDs) and intraarticular corticosteroids do not succeed.</s><s>According to the ACR recommendations, MTX treatment is also advised in patients with oligoarthritis who have high disease activity and poor prognostic features <ref type="bibr" target="#b0">(1)</ref>.</s><s>If the response to MTX is insufficient or also in high-risk disease, rapid escalation to include biologic DMARDs, namely a TNF inhibitor, is encouraged (1).</s><s>Considering our study results, it is important to discuss whether a high uveitis risk should also be considered as an indication for early MTX therapy in terms of a riskadapted strategy.</s><s>As our data clearly show a reduced risk for uveitis under MTX, JIA patients at higher risk for uveitis (ANA positive, oligoarthritis, young age at JIA onset) might benefit from an immunosuppressive treatment, even if arthritis is stable under NSAIDs or corticosteroid treatment.</s><s>Indeed, DMARD treatment in oligoarthritis patients age ,3 years at arthritis onset (17.9% versus 6.1%; OR 3.63, P , 0.001) and with a high active disease at baseline (cJADAS-10 .10,</s><s>16.5% versus 7.6%; OR 2.24, P 5 0.003) may significantly reduce the risk for uveitis, according to our data.</s></p><p><s>This study was performed using data from a prospective, nationwide database.</s><s>The large patient cohort is representative for all JIA patients in Germany.</s><s>As the majority of cases of uveitis present within the first 4 years <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b71">71)</ref>, the followup time of our study should allow us to identify the majority of uveitis manifestations in the analyzed study cohort.</s><s>A relevant limitation of the NPDR is the documentation interval of 1 year, with missing timedependent data in between.</s><s>Using this method, it is not possible to determine whether the particular DMARD treatment was instituted before or after uveitis onset during the first year after JIA onset and what the indication for therapy was (arthritis and/or uveitis).</s><s>As no dosing information for DMARDs is collected in the case report forms of the NPDR, it cannot be excluded that uveitis manifestation despite DMARD treatment may be due to dosing in individual patients.</s><s>Nevertheless, the high patient numbers of the largest JIA databases worldwide should balance potential biases between patient groups.</s></p><p><s>In conclusion, this prospective population-based study corroborates published data on the JIA-associated uveitis incidence in Central Europe.</s><s>In addition to specific disease characteristics (e.g., disease onset after age 6 years, ANA negativity, and a disease category other than oligoarthritis), early treatment with MTX was associated with a lower risk of uveitis in JIA patients.</s><s>This protective effect was highest for a combination of MTX with a TNF inhibitor (mainly etanercept was used in this study).</s><s>Further studies are needed to show whether early treatment in JIA patients could improve the outcome by preventing uveitis onset with all the consequences for visual acuity, ocular complications and, last but not least, quality of life.</s><s>Therefore, in addition to the severe course of arthritis, preventing uveitis may constitute another indication for DMARD treatment.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Predicted survival curves for the time of juvenile idiopathic arthritis (JIA) onset to occurrence of uveitis with respect to disease-modifying antirheumatic drug (DMARD) treatment in the last 12 months before uveitis onset.</s><s>Survival curves show the estimated proportion of patients without uveitis onset for no DMARD, methotrexate (MTX) monotherapy (n 5 953; HR 0.63, P 5 0.022), tumor necrosis factor inhibitor (TNF inh.) monotherapy (n 5 48; HR 0.56, P 5 0.001), or a combination of the two (n 5 436; HR 0.10, P 5 0.001); n 5 3,332 patients with JIA.</s></p></div></figDesc><graphic coords="5,71.26,83.96,223.37,119.91" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Predicted survival curves for the time of juvenile idiopathic arthritis (JIA) onset to occurrence of uveitis with respect to early disease-modifying antirheumatic drug (DMARD) treatment.</s><s>Curves for patients without early DMARDs, early methotrexate (MTX) monotherapy (n 5 41; HR 0.29, P &lt; 0.001) and a combination of MTX and a tumor necrosis factor inhibitor (TNF inh.; n 5 61; HR 0.15, P 5 0.002) within the first year of JIA disease are shown.</s><s>The y-axis shows the estimated cumulative proportion of patients without uveitis during followup; n 5 3,332 patients with JIA.</s></p></div></figDesc><graphic coords="6,71.26,83.96,223.37,119.91" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Impact of systemic antiinflammatory treatment on the onset of uveitis in patients with JIA.</s><s>Demographic characteristics at baseline (first documentation) in the</s></p></div></figDesc><table><row><cell>registry for patients with JIA (n 5 3,512)*</cell><cell>All patients, uveitis, no. (%) within the first year Patients without Patients with uveitis onset Patients with uveitis onset after first year</cell><cell>no. (%) or or mean 6 SD No. (%) or OR No. (%) or</cell><cell>mean 6 SD (reference) mean 6 SD (95% CI), P † mean 6 SD OR (95% CI), P †</cell><cell>No. of patients 3,512 3,081 180 -251 -</cell><cell>Female sex 2,307 (65.7) 2,006 (65.1) 123 (68.3) 0.86 (0.63-1.19), 0.377 178 (70.9) 0.77 (0.58-1.01), 0.063</cell><cell>Age, years 8.3 6 4.8 8.6 6 4.8 6.2 6 3.9 0.89 (0.86-0.92), , 0.001 5.3 6 4.0 0.84 (0.81-0.87), , 0.001</cell><cell>Age at arthritis onset, years 7.8 6 4.8 8.1 6 4.8 5.7 6 3.9 0.89 (0.86-0.92), , 0.001 4.9 6 4.0 0.84 (0.81-0.87), , 0.001</cell><cell>Age at uveitis onset, years 7.0 6 4.2 -5.9 6 4.1 P , 0.001 ‡ 7.9 6 4.2 P , 0.001 ‡</cell><cell>JIA category</cell><cell>RF-positive polyarthritis 103 (2.9) 97 (3.2) 2 (1.1) 1.15 (0.46-2.90), 0.763 4 (1.6) 0.63 (0.25-1.55), 0.310</cell><cell>RF-negative polyarthritis 578 (16.5) 515 (16.7) 22 (12.2) 1.79 (1.11-2.90), 0.017 41 (16.3) 1.21 (0.85-1.73), 0.283</cell><cell>Systemic JIA 227 (6.5) 222 (7.2) 0 (0.0) 0.13 (0.07-0.24), , 0.001 5 (2.0) 0.34 (0.15-0.76), 0.009</cell><cell>Persistent oligoarthritis 1,749 (49.8) 1,480 (48.0) 127 (70.6) 3.51 (2.42-5.07), , 0.001 142 (56.6) 1.46 (1.12-1.91), 0.005</cell><cell>Extended oligoarthritis 137 (3.9) 111 (3.6) 9 (5.0) 3.58 (1.93-6.66), , 0.001 17 (6.8) 2.34 (1.43-3.85), 0.001</cell><cell>Psoriatic arthritis 174 (5.0) 159 (5.2) 3 (1.7) 0.96 (0.42-2.20), 0.918 12 (4.8) 1.15 (0.66-2.01), 0.619</cell><cell>Enthesitis-related arthritis 398 (11.3) 367 (11.9) 11 (6.1) 1.30 (0.73-2.31), 0.370 20 (8.0) 0.83 (0.53-1.30), 0.419</cell><cell>Disease activity, physician global NRS 0-10 2.8 6 2.2 2.8 6 2.2 3.2 6 2.4 1.09 (1.02-1.16), 0.013 3.2 6 2.3 1.08 (1.02-1.15), 0.005</cell><cell>ESR, mm/hour 21.8 6 20.6 21.3 6 20.5 23.1 6 19.0 1.00 (0.99-1.01), 0.277 27.7 6 22.4 1.01 (1.005-1.02), , 0.001</cell><cell>ESR .35 445 (18.5) 373 (17.6) 23 (19.2) 1.11 (0.70-1.78), 0.652 49 (29.9) 2.00 (1.41-2.85), , 0.001</cell><cell>JADAS-10 9.7 6 6.6 9.6 6 6.5 9.6 6 6.1 1.00 (0.97-1.03), 0.932 11.6 6 7.1 1.04 (1.02-1.07), , 0.001</cell><cell>JADAS-10 score .10 763 (39.0) 652 (37.8) 41 (41.4) 1.16 (0.77-1.76), 0.932 70 (52.6) 1.83 (1.28-2.61), 0.001</cell><cell>cJADAS-10 7.8 6 5.8 7.7 6 5.8 8.0 6 5.3 1.01 (0.98-1.03), 0.606 8.8 6 6.1 1.03 (1.01-1.05), 0.010</cell><cell>cJADAS-10 score .10 787 (28.0) 668 (27.1) 41 (28.9) 1.09 (0.75-1.59), 0.640 78 (38.1) 1.65 (1.23-2.22), 0.001</cell><cell>ANA positive 1,549 (53.2) 1,265 (49.6) 129 (86.6) 6.55 (4.06-10.56), , 0.001 155 (73.1) 2.76 (2.02-3.78), , 0.001</cell><cell>C-HAQ total score 0.39 6 0.54 0.38 6 0.53 0.35 6 0.49 0.89 (0.65-1.23), 0.486 0.53 6 0.62 1.52 (1.20-1.92), , 0.001</cell><cell>Systemic antiinflammatory</cell><cell>treatment in previous 12 months</cell><cell>Synthetic DMARD 909 (36.8) 781 (36.0) 65 (50.8) 1.84 (1.29-2.63), 0.001 63 (36.4) 1.02 (0.74-1.41), 0.904</cell><cell>Methotrexate 777 (29.7) 663 (28.9) 58 (41.1) 1.72 (1.21-2.43), 0.002 56 (29.8) 1.04 (0.75-1.44), 0.803</cell><cell>Azathioprine 12 (0.5) 11 (0.5) 1 (0.7) -0 (0.0) -</cell><cell>Cyclosporine A 8 (0.4) 7 (0.4) 1 (0.8) -0 (0.0) -</cell><cell>Biologic DMARD 58 (2.1) 48 (2.0) 5 (3.4) 1.77 (0.69-4.50), 0.234 5 (2.5) 1.27 (0.50-3.23), 0.612</cell><cell>Etanercept 49 (2.1) 41 (2.0) 3 (2.3) 1.18 (0.36-3.88), 0.781 5 (2.9) 1.51 (0.59-3.86), 0.394</cell><cell>Adalimumab 4 (0.3) 2 (0.2) 2 (3.0) 18.53 (2.57-133.74), 0.004 0 (0.0) -</cell><cell>Infliximab 0 (0) 0 (0) 0 (0) -0 (0) -</cell><cell>Corticosteroids, systemic 470 (19.4) 418 (19.9) 17 (13.3) 0.62 (0.37-1.04), 0.071 35 (18.8) 0.94 (0.64-1.37), 0.735</cell><cell>Corticosteroids, #0.15 mg/kg 274 (10.0) 243 (10.2) 9 (6.3) 0.59 (0.30-1.18), 0.135 22 (10.7) 1.05 (0.66-1.67), 0.827</cell><cell>Corticosteroids, .0.15 mg/kg 263 (9.6) 232 (9.7) 11 (7.7) 0.77 (0.41-1.45), 0.426 20 (9.7) 1.00 (0.62-1.62), 0.996</cell><cell>Corticosteroids, intraarticular 127 (5.3) 113 (5.4) 5 (3.9) 0.72 (0.29-1.79), 0.473 9 (4.9) 0.90 (0.45-1.81), 0.767</cell><cell>NSAIDs 1,889 (68.4) 1,646 (68.2) 96 (67.1) 0.95 (0.66-1.36), 0.788 147 (71.4) 1.16 (0.85-1.59), 0.352</cell><cell>* JIA 5 juvenile idiopathic arthritis; OR 5 odds ratio; 95% CI 5 95% confidence interval; RF 5 rheumatoid factor; NRS 5 numerical rating scale; ESR 5 erythrocyte sedimentation rate; JADAS 5</cell><cell>Juvenile Arthritis Disease Activity Score; cJADAS 5 clinical JADAS; ANA 5 antinuclear antibody; C-HAQ 5 Childhood Health Assessment Questionnaire; DMARD 5 disease-modifying antirheumat-</cell></row></table><note><p><s>ic drug; NSAIDs 5 nonsteroidal antiinflammatory drugs.†</s><s>OR estimated by univariate logistic regression analysis.‡</s><s>Comparing patients with uveitis onset within and after the first 12 months of JIA.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>At first documentation, mean 6 SD age was 8.3 6 4.8 years and mean 6 SD duration of JIA was 5.6 6 3.4 months.</s><s>Mean 6 SD total followup time was 3.6 6 2.4 years.</s></p></div></figDesc><table><row><cell>Baseline characteristics. A total of 3,512 JIA patients</cell></row><row><cell>(65.7% female, 53.2% ANA positive) fulfilled the inclu-</cell></row><row><cell>sion criteria. Patients were enrolled in 60 pediatric rheu-</cell></row><row><cell>matologic centers (2002: 27 centers with a mean of 101</cell></row><row><cell>patients per center; 2013: 60 centers with a mean of 88</cell></row><row><cell>patients per center). Demographic characteristics and</cell></row><row><cell>ILAR category classifications are shown in</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>In a multivariate logistic regression model, demographic and clinical risk factors of uveitis were a younger age at JIA onset (OR 1.21, 95% CI 1.16-1.27,</s><s>P , 0.001), enthesitis-related arthritis (OR 1.95, 95% CI 1.09-3.49,</s><s>P 5 0.024), ANA positivity (OR 1.85,</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Overview of systemic treatment with synthetic and biologic DMARDs for patients without uveitis onset within the first year of disease (n 5 3,332 JIA patients)*</s></p></div></figDesc><table><row><cell>Systemic antiinflammatory</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>treatment during previous</cell><cell>Year 1</cell><cell>Year 2</cell><cell>Year 3</cell><cell>Year 4</cell><cell>Year 5</cell><cell>Year 6</cell><cell>Year 7</cell></row><row><cell>12 months</cell><cell>(n 5 3,322)</cell><cell>(n 5 2,845)</cell><cell>(n 5 2,196)</cell><cell>(n 5 1,697)</cell><cell>(n 5 1,090)</cell><cell>(n 5 743)</cell><cell>(n 5 532)</cell></row><row><cell>Synthetic DMARD</cell><cell>735 (30.5)</cell><cell cols="2">1,301 (53.3) 1,128 (59.6)</cell><cell>821 (54.8)</cell><cell>479 (48.5)</cell><cell cols="2">294 (43.3) 210 (43.6)</cell></row><row><cell>Methotrexate</cell><cell>719 (29.0)</cell><cell cols="2">1,285 (52.3) 1,106 (57.9)</cell><cell>797 (52.8)</cell><cell>457 (46.8)</cell><cell cols="2">280 (41.2) 200 (41.6)</cell></row><row><cell>Azathioprine</cell><cell>11 (0.4</cell><cell>17 (0.7)</cell><cell>22 (1.2)</cell><cell>21 (1.4)</cell><cell>16 (1.6)</cell><cell>14 (2.1)</cell><cell>10 (2.1)</cell></row><row><cell>Cyclosporine A</cell><cell>7 (0.3)</cell><cell>4 (0.2)</cell><cell>5 (0.4)</cell><cell>3 (0.3)</cell><cell>2 (0.3)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell></row><row><cell>Others</cell><cell>3 (0.1)</cell><cell>2 (0.1)</cell><cell>4 (0.3)</cell><cell>1 (0.1)</cell><cell>1 (0.1)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell></row><row><cell>Biologic DMARD</cell><cell>53 (2.0)</cell><cell>168 (6.7)</cell><cell>245 (12.5)</cell><cell>229 (15.1)</cell><cell>151 (15.4)</cell><cell>114 (16.6)</cell><cell>92 (19.0)</cell></row><row><cell>Etanercept</cell><cell>46 (2.1)</cell><cell>149 (6.1)</cell><cell>199 (10.4)</cell><cell>184 (12.2)</cell><cell>121 (12.4)</cell><cell>94 (13.8)</cell><cell>74 (15.4)</cell></row><row><cell>Adalimumab</cell><cell>2 (0.2)</cell><cell>8 (0.5)</cell><cell>22 (1.6)</cell><cell>28 (2.2)</cell><cell>13 (1.5)</cell><cell>15 (2.2)</cell><cell>13 (2.7)</cell></row><row><cell>Infliximab</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell>2 (0.2)</cell><cell>3 (0.2)</cell><cell>4 (0.5)</cell><cell>0 (0.0)</cell><cell>1 (0.2)</cell></row><row><cell>Others</cell><cell>5 (0.4)</cell><cell>12 (0.8)</cell><cell>24 (1.7)</cell><cell>15 (1.1)</cell><cell>13 (1.5)</cell><cell>7 (1.1)</cell><cell>6 (1.2)</cell></row><row><cell>Corticosteroids systemic</cell><cell>453 (19.8)</cell><cell>439 (19.4)</cell><cell>251 (14.7)</cell><cell>132 (9.9)</cell><cell>67 (8.3)</cell><cell>47 (8.5)</cell><cell>38 (9.3)</cell></row><row><cell>Corticosteroids, #0.15 mg/kg</cell><cell>265 (10.2)</cell><cell>388 (15.4)</cell><cell>230 (12.3)</cell><cell>118 (7.9)</cell><cell>59 (6.3)</cell><cell>45 (7.0)</cell><cell>39 (8.3)</cell></row><row><cell>body weight/day</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Corticosteroids, .0.15 mg/kg</cell><cell>252 (9.7)</cell><cell>113 (4.5)</cell><cell>45 (2.4)</cell><cell>29 (2.0)</cell><cell>16 (1.7)</cell><cell>8 (1.3)</cell><cell>4 (0.9)</cell></row><row><cell>body weight/day</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NSAIDs</cell><cell cols="3">1,793 (68.5) 2,044 (80.1) 1,192 (63.0)</cell><cell>700 (46.9)</cell><cell>410 (43.5)</cell><cell cols="2">251 (39.0) 195 (41.0)</cell></row></table><note><p><s>P 5 0.418) and female sex (OR 1.23, 95% CI 0.86-1.75,</s><s>P 5 0.250) did not change significantly the risk for uveitis.</s><s>Whereas an erythrocyte sedimentation rate (ESR) .35</s><s>mm/hour (OR 2.00, 95% CI 1.41-2.85,</s><s>P , 0.001) or a high C-HAQ total score at baseline (OR 1.52, 95% CI 1.20-1.92,</s><s>P , 0.001) were significantly associated with uveitis onset in the univariate analysis (Table</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Multivariable regression analysis for the impact of DMARD treatment and cJADAS-10 on the onset of uveitis in JIA (n 5 3,332)*</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>JIA patients</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>JIA patients</cell><cell>with uveitis onset</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>without uveitis</cell><cell>during followup</cell><cell>HR †</cell><cell>95% CI</cell><cell>P †</cell></row><row><cell>Use of MTX ‡</cell><cell>1,669 (64.1)</cell><cell>132 (52.6)</cell><cell>0.63</cell><cell>0.42-0.94</cell><cell>0.022</cell></row><row><cell>Early use of MTX during first</cell><cell>818 (26.6)</cell><cell>41 (16.3)</cell><cell>0.29</cell><cell>0.19-0.45</cell><cell>, 0.001</cell></row><row><cell>year after arthritis onset</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Use of biologic DMARD ‡</cell><cell>462 (15)</cell><cell>22 (8.8)</cell><cell>0.56</cell><cell>0.38-0.81</cell><cell>, 0.001</cell></row><row><cell>Early use of biologic DMARDs during</cell><cell>134 (4.4)</cell><cell>5 (2.0)</cell><cell>0.51</cell><cell>0.18-1.47</cell><cell>0.214</cell></row><row><cell>first year after arthritis onset</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>MTX plus TNF-inhibitor ‡</cell><cell>414 (17.1)</cell><cell>22 (10.2)</cell><cell>0.10</cell><cell>0.05-0.23</cell><cell>, 0.001</cell></row><row><cell>cJADAS-10</cell><cell>3.5 (3.9)</cell><cell>4.6 (4.2)</cell><cell>1.06</cell><cell>1.01-1.12</cell><cell>0.044</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">* Values are the number of patients (percentage). DMARDs 5 disease-modifying antirheumatic drugs; JIA 5 juvenile idiopathic arthritis; NSAIDs 5 nonsteroidal antiinflammatory drugs.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">* Values are the number (percentage) unless indicated otherwise. DMARD 5 disease-modifying antirheumatic drug; cJADAS-10 5 clinical Juvenile Arthritis Disease Activity Score; JIA 5 juvenile idiopathic arthritis; HR 5 hazard ratio; 95% CI 5 95% confidence interval; MTX 5 methotrexate; TNF 5 tumor necrosis factor.† Adjusted for antinuclear antibody positivity, International League of Associations for Rheumatology category, age at JIA onset, disease duration and cJADAS-10, therapy with glucocorticoids, MTX, and biologic DMARDs during followup. ‡ For patients with uveitis onset, treatment in the year before uveitis onset was evaluated, whereas for patients without uveitis, the year before the last documentation was analyzed.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>The authors thank the patients and their parents for participating in the NPRD.</s><s>In addition, the authors thank all investigators who participated in the NPRD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head><p><s>All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication.</s><s>Dr. Tappeiner had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</s><s>Study conception and design.</s><s>Tappeiner, Schenck, Niewerth, Heiligenhaus, Minden, Klotsche.</s><s>Acquisition of data.</s><s>Minden.</s><s>Analysis and interpretation of data.</s><s>Tappeiner, Schenck, Niewerth, Heiligenhaus, Minden, Klotsche.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ROLE OF THE STUDY SPONSOR</head><p><s>Pfizer Pharma had no role in the study design or in the collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication.</s><s>Publication of this article was not contingent upon approval by Pfizer Pharma.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features</title>
		<author>
			<persName><forename type="first">T</forename><surname>Beukelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Patkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Saag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tolleson-Rinehart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Q</forename><surname>Cron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Dewitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="465" to="482" />
			<date type="published" when="2011">2011. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Dueckers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Guellac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Arbogast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dannecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Foeldvari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Frosch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="176" to="193" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">B</forename><surname>Prakken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Albani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Martini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page" from="2138" to="2149" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ravelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Martini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="767" to="778" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kotaniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kautiainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Karma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Aho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ophthalmology</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="2071" to="2075" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Carvounis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Burke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Graefes Arch Clin Exp Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">244</biblScope>
			<biblScope unit="page" from="281" to="290" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines</title>
		<author>
			<persName><forename type="first">A</forename><surname>Heiligenhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Niewerth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ganser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Heinz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Minden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1015" to="1019" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Thorne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Woreta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Jabs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ophthalmology</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="1436" to="1441" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Thorne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Woreta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Kedhar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Jabs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="840" to="846" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Visual outcomes prognosticators in juvenile rheumatoid arthritisassociated uveitis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Dana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Merayo-Lloves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Schaumberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Foster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ophthalmology</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="236" to="244" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Saving the vision of children with juvenile rheumatoid arthritis-associated uveitis</title>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">D</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Foster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="1133" to="1134" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Secondary glaucoma in patients with juvenile rheumatoid arthritis-associated iridocyclitis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Havrlikova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Baltatzis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Christen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Merayo-Lloves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Ophthalmol Scand</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="576" to="579" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Saurenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Levin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Laxer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Silverman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1824" to="1828" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Saurenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Levin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Laxer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="647" to="657" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors</title>
		<author>
			<persName><forename type="first">A</forename><surname>Heiligenhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Heinz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Edelsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kotaniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Minden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ocul Immunol Inflamm</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="180" to="191" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry</title>
		<author>
			<persName><forename type="first">Angeles-Han</forename><surname>St</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Pelajo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Vogler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rouster-Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kennedy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ponder</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="2088" to="2096" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Anink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Otten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Gorter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Prince</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Van Rossum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Den Berg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1674" to="1679" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Otten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Prince</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Anink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cate</forename><surname>Ten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hoppenreijs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Armbrust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="721" to="727" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Biological therapy with TNF-inhibitors in pediatric rheumatology: review of the literature and personal experience</title>
		<author>
			<persName><forename type="first">V</forename><surname>Gerloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pontikaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gattinara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fantini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Reumatismo</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="244" to="261" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>In Italian</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ruperto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gerloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wulffraat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>De Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Falcini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="2191" to="2201" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Windschall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Horneff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="61" to="69" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry</title>
		<author>
			<persName><forename type="first">H</forename><surname>Schmeling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Minden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Foeldvari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ganser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hospach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Horneff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="2580" to="2589" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children&apos;s Study Group</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Giannini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Brewer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kuzmina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shaikov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maximov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Vorontsov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<editor>U.S.A.-U.S.S.R.</editor>
		<imprint>
			<biblScope unit="volume">326</biblScope>
			<biblScope unit="page" from="1043" to="1049" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>Methotrexate in resistant juvenile rheumatoid arthritis: results of the</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Current treatments for juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Quartier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Joint Bone Spine</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="511" to="516" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Trachana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pratsidou-Gertsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pardalos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kozeis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Badouraki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kanakoudi-Tsakalidou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="101" to="107" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO</title>
		<author>
			<persName><forename type="first">K</forename><surname>Minden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Niewerth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Seipelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Foeldvari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Girschick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1407" to="1415" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type</title>
		<author>
			<persName><forename type="first">P</forename><surname>Quartier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Taupin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bourdeaut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lemelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pillet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bost</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1093" to="1101" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Response of pediatric uveitis to tumor necrosis factor-a inhibitors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Burnham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hennessy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1394" to="1403" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Papadopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kostik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bohm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Nieto-Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Gonzalez-Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pistorio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="879" to="884" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The decreasing prevalence of uveitis associated with juvenile rheumatoid arthritis: do NSAIDs play a role?</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Daud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wipfl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Pepmueller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">V</forename><surname>Davitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Moore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="151" to="155" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Petty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Southwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Manners</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Glass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Goldenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="390" to="392" />
			<date type="published" when="2001">2001. 2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">German Study Group of Pediatric Rheumatologists. Health care provision in pediatric rheumatology in Germany: national rheumatologic database</title>
		<author>
			<persName><forename type="first">K</forename><surname>Minden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Niewerth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Listing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="622" to="628" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The clinical meaning of functional outcome scores in children with juvenile arthritis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Dempster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Porepa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Feldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1768" to="1774" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score</title>
		<author>
			<persName><forename type="first">A</forename><surname>Consolaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Negro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chiara</forename><surname>Gallo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bracciolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schiappapietra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1703" to="1709" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Development and validation of a composite disease activity score for juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Consolaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ruperto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bazso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pistorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Magni-Manzoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Filocamo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="658" to="666" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Discrete-time methods for the analysis of event histories</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Allison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sociological Methodology</title>
		<editor>Leinhardt S</editor>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="61" to="98" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Time-aggregation bias in hazard-rate models with covariates</title>
		<author>
			<persName><forename type="first">T</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Koput</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sociol Methods Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="25" to="51" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">A novel nonparametric approach for estimating cut-offs in continuous risk indicators with application to diabetes epidemiology</title>
		<author>
			<persName><forename type="first">J</forename><surname>Klotsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ferger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pieper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Wittchen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Med Res Methodol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">63</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Leflunomide or methotrexate for juvenile rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Silverman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mouy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Spiegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Saurenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lahdenne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="page" from="1655" to="1666" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">and the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Lovell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Giannini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reiff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Cawkwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Silverman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Nocton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">342</biblScope>
			<biblScope unit="page" from="763" to="769" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register</title>
		<author>
			<persName><forename type="first">J</forename><surname>Anink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Otten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Prince</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Hoppenreijs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Wulffraat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Swart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="712" to="717" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Prevention of experimental allergic uveitis: treatment and methotrexate</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Mcmaster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">G</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Owens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kyriakos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="835" to="837" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF a agents</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Saurenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Levin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Laxer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Silverman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="833" to="836" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">The frequency and outcome of uveitis in patients with newly diagnosed juvenile idiopathic arthritis in two 4-year cohorts from</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kotaniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sihto-Kauppi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Salomaa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Saila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ristolainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kauppi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="143" to="147" />
			<date type="published" when="1990">1990-1993 and 2000-2003. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Ramanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Dick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Benton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Compeyrot-Lacassagne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dawoud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hardwick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trials</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">14</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Uveitis as a cause of visual loss in arthritides and comparable conditions</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kotaniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Aho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kotaniemi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="309" to="312" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Uveitis and juvenile idiopathic arthritis: a cohort study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Benezra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Behar-Cohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="513" to="518" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Chalom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Goldsmith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Koehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bittar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Ostrov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2031" to="2034" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Prevalence of uveitis in an outpatient juvenile arthritis clinic: onset of uveitis more than a decade after onset of arthritis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Akduman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tychsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr Ophthalmol Strabismus</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="101" to="106" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Screening for uveitis in juvenile rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Boone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Cruz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr Ophthalmol Strabismus</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="41" to="43" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Bowyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Roettcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wallace</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="394" to="400" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Cassidy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Levinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Bass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Brewer</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Fink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="274" to="281" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Grassi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Corona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Casellato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Carnelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bardare</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1139" to="1145" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Clinical patterns of chronic iridocyclitis in children with juvenile rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Cassidy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Petty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="224" to="227" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Saurenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tyrrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Laxer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="1974" to="1984" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">A population-based study on uveitis in juvenile rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kotaniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kaipiainen-Seppanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Savolainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Karma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="119" to="122" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Incidence of arthritis in urban Finnish children: a prospective study</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kunnamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kallio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pelkonen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1232" to="1238" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Course, complications, and outcome of juvenile arthritis-related uveitis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sabri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Saurenmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Silverman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Levin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J AAPOS</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="539" to="545" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Prognosis of juvenile rheumatoid arthritisassociated uveitis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Paroli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Speranza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Marino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Pirraglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pivetti-Pezzi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="616" to="621" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Juvenile arthritisassociated uveitis: visual outcomes and prognosis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Roberton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Hammerton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="614" to="620" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Extended oligoarthritis and other risk factors for developing JIA-associated uveitis under ILAR classification and its implication for current screening guideline</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Sim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Venning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Gregson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Amoaku</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ocul Immunol Inflamm</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="353" to="357" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Visual outcome of juvenile rheumatoid arthritis-associated uveitis in adults</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Ozdal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Vianna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Deschenes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ocul Immunol Inflamm</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="33" to="38" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">The uveitis and its relationship with disease activity and quality of life in Moroccan children with juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ezzahri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Amine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rostom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Rifay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Badri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mawani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1387" to="1391" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">The relationship between ocular and articular disease activity in children with juvenile rheumatoid arthritis and associated uveitis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Oen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="797" to="800" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Pediatric Outcomes Data Collection Instrument (PODCI), and Activities Scale for Kids (ASK)</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Klepper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Juvenile Arthritis Functional Assessment Scale (JAFAS)</title>
				<imprint>
			<date type="published" when="2011">2011</date>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="S371" to="S382" />
		</imprint>
	</monogr>
	<note>Measures of pediatric function: Child Health Assessment Questionnaire (C-HAQ). Suppl</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Zulian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Martini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Falcini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gerloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Zannin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pinello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2446" to="2453" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Uveitis as a marker of active arthritis in 372 patients with juvenile idiopathic seronegative oligoarthritis or polyarthritis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kotaniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kotaniemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Savolainen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="109" to="112" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Predictive value of selected biomarkers, polymorphisms, and clinical features for oligoarticular juvenile idiopathic arthritisassociated uveitis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Pelegrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Casaroli-Marano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anton</forename><forename type="middle">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Carmen</forename><surname>Garcia De Vicuna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Molina-Prat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Ignacio</forename><surname>Arostegui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ocul Immunol Inflamm</title>
		<imprint>
			<biblScope unit="volume">2013</biblScope>
			<biblScope unit="page" from="1" to="5" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Erythrocyte sedimentation rate as baseline predictor for the development of uveitis in children with juvenile idiopathic arthritis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Haasnoot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Tent-Hoeve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Wulffraat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Schalij-Delfos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">I</forename><surname>Los</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Armbrust</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="372" to="377" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Risk factors and longterm outcome of juvenile idiopathic arthritisassociated uveitis in Switzerland</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Bolt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cannizzaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Seger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Saurenmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="703" to="706" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Arthritis and uveitis in children: a pediatric rheumatology perspective</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Petty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Rosenbaum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="879" to="884" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
